Psilocybin's anti-inflammatory and neuroplastic effects are being examined for whether they could help protect the aging brain and reduce dementia-related decline

Psilocybin is being investigated as a possible tool for protecting the aging brain by reducing inflammation, promoting neuroplasticity, and potentially slowing processes linked to cognitive decline. Interest centers on whether psychedelic compounds can do more than treat mood symptoms and instead influence biological pathways involved in dementia and age-related brain dysfunction. Emerging research connects chronic neuroinflammation, stress, and impaired neural connectivity with disorders such as Alzheimer's disease. Psilocybin's effects on serotonin receptors, mood, and brain network flexibility make it a candidate for testing in older adults, especially where depression, isolation, and cognitive decline overlap. Key uncertainty remains around dosage, safety, durability of benefit, and whether microdosing or full psychedelic dosing would be appropriate in aging populations. The broader significance lies in expanding psychedelic science from mental health treatment into prevention and neurodegenerative care.